MARTINSRIED, GERMANY and MUNICH, GERMANY--(Marketwire - May 23, 2012) -
MorphoSys AG /
AbD Serotec to Launch Panel of HuCAL Anti-Drug Antibodies Supporting the
Development of Novel Antibody Therapeutics.
Processed and transmitted by Thomson Reuters ONE.
The issuer is solely responsible for the content of this announcement.
New Product Category Targets Contract Research Organizations and
MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX) announced today
division for research and diagnostic antibodies, AbD Serotec, will
series of novel anti-drug antibodies (ADAs) to strengthen its position
leading provider of diagnostic reagents. Starting with the recent
fully human, recombinant antibodies binding Rituximab
Trastuzumab (Herceptin®), AbD Serotec plans to expand this product
with antibodies against Alemtuzumab (Campath®), Bevacizumab
Infliximab (Remicade®), Ustekinumab (Stelara®), and Adalimumab
in the near future.* Other anti-drug antibodies can be requested as part
custom antibody service of AbD Serotec.
"Anti-drug antibodies are ideal for preclinical and clinical research to
the development of novel antibody drugs as well as biosimilars,"
Dieter Feger, Head of AbD Serotec. "We see an increasing demand for these
from clinical research organizations, biopharmaceutical and
companies. Due to the recombinant nature of our HuCAL technology, AbD
able to deliver an unlimited, secure and batch to batch consistent
these assay reagents for extensive clinical studies."
The Human Combinatorial Antibody Library can deliver highly specific,
high-affinity monoclonal antibodies against any given antibody
unprecedented success rates. The highly specific HuCAL ADAs are developed
in vitro, pre-adsorbed against any available controls and human serum. An
to screen for inhibiting or neutralizing antibodies is also
unlimited, consistent supply eliminates the need for revalidation of new
in extensive clinical studies. Other advantages include the
convert selected ADAs into various other human isotypes and Ig subclasses.
provides customers with a single antibody solution for both immune
pharmacokinetic assays ultimately saving assay development resources.
* Not all anti-drug antibodies might be available in all countries
MorphoSys developed HuCAL, the most successful antibody library technology
the pharmaceutical industry. By successfully applying this and other
technologies, MorphoSys has become a leader in the field of therapeutic
antibodies, one of the fastest-growing drug classes in human healthcare.
company's AbD Serotec unit uses HuCAL and other antibody technologies to
generate superior monoclonal antibodies for research and diagnostic
Together with its pharmaceutical partners, MorphoSys has built a
pipeline of more than 70 human antibody drug candidates for the treatment
cancer, rheumatoid arthritis, and Alzheimer's disease, to name just a few.
its ongoing commitment to new antibody technology and drug development,
MorphoSys is focused on making the healthcare products of tomorrow.
listed on the Frankfurt Stock Exchange under the symbol MOR. For regular
about MorphoSys, visit http://www.morphosys.com
HuCAL®, HuCAL GOLD®, HuCAL PLATINUM®,
CysDisplay®, RapMAT® and
arYla® are registered trademarks of MorphoSys.
This communication contains certain forward-looking statements
MorphoSys group of companies. The forward-looking statements contained
represent the judgment of MorphoSys as of the date of this release and
risks and uncertainties. Should actual conditions differ from the
assumptions, actual results and actions may differ from those
MorphoSys does not intend to update any of these forward-looking
far as the wording of the relevant press release is concerned.
Media Release (PDF):
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: MorphoSys AG via Thomson Reuters ONE